Krystal Biotech Inc’s recently made public that its President, R&D Krishnan Suma unloaded Company’s shares for reported $4.27 million on Mar 11 ’24. In the deal valued at $170.96 per share,25,000 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,550,882 shares worth roughly $251.3 million.
Then, Krishnan Krish S sold 25,000 shares, generating $4,274,040 in total proceeds. Upon selling the shares at $170.96, the President and CEO now owns 1,550,882 shares.
Before that, Krishnan Suma sold 25,000 shares. Krystal Biotech Inc shares valued at $4,273,679 were divested by the President, R&D at a price of $170.95 per share. As a result of the transaction, Krishnan Suma now holds 1,612,262 shares, worth roughly $261.25 million.
Goldman initiated its Krystal Biotech Inc [KRYS] rating to a Buy in a research note published on November 20, 2023; the price target was $160. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late October with a ‘”an Overweight”‘ rating. Citigroup began covering KRYS with “Buy” recommendation on October 12, 2023. Berenberg started covering the stock on September 07, 2023. It rated KRYS as “a Buy”.
Price Performance Review of KRYS
On Tuesday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock jump 3.05% to $162.04. Over the last five days, the stock has lost -4.73%. Krystal Biotech Inc shares have risen nearly 30.61% since the year began. Nevertheless, the stocks have risen 86.57% over the past one year. While a 52-week high of $189.97 was reached on 03/05/24, a 52-week low of $82.09 was recorded on 02/22/24. SMA at 50 days reached $160.30, while 200 days put it at $127.99. A total of 0.22 million shares were traded, compared to the trading of 0.34 million shares in the previous session.
Levels Of Support And Resistance For KRYS Stock
The 24-hour chart illustrates a support level at 158.40, which if violated will result in even more drops to 154.75. On the upside, there is a resistance level at 165.21. A further resistance level may holdings at 168.37. The Relative Strength Index (RSI) on the 14-day chart is 43.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -12.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.95%. Stochastics %K at 12.64% indicates the stock is a buying.
The most recent change occurred on April 18, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $102 price target.
